UAE’s Neopharma and ASKA of Japan to build drug plant in India in $53M JV

Taj mahal on a bright day in Agra, India
UAE-based drugmaker Neopharma and ASKA Pharma of Tokyo will build a $53 million pharmaceutical manufacturing facility in India. (Somchaisom/Getty Images)

United Arab Emirates-based drugmaker Neopharma and ASKA Pharmaceuticals of Tokyo entered a joint venture to build a $53 million (₹350-crore) pharmaceutical manufacturing facility to be operated by Neopharma subsidiary Omnicare Drugs India in Visakhapatnam.

The plant is expected to open by 2020 and will produce oral solid dosage forms, oral liquids and topical preparations. The capacity of the facility is projected at 3 billion tablets a year, The Hindu reported.

The joint venture aims to manufacture drugs for chronic therapies in cardiovascular diseases, the central nervous system and diabetes, along with other products from key therapeutic classes targeting Japan and the world market.

Cambrex Webinar

Understanding the Importance of Crystallization Processes to Avoid Unnecessary Cost, Risk and Development Delays

Wednesday, May 27, 2020 | 10am ET / 7am PT

A well-developed crystallization process can produce suitable particles that can facilitate consistent filtration, drying and formulation of the API and allow confident and reliable manufacturing of the final drug product, while avoiding unnecessary cost, risk and development delays.

Construction is set to begin this month at a site in J.N. Pharma City. The company said it will seek cGMP accreditation from all major global health regulatory bodies.

"The partnership will enable us to transfer skills and knowledge locally," B.R. Shetty, Neopharma’s chairman, said in a statement.

Last summer, Neopharma announced it would build a $100 million plant in Abu Dhabi. That news came just weeks after the drugmaker said it would spend more than twice that for manufacturing plant and development rights to a diabetes treatment in Japan.

Suggested Articles

The eight-year deal will initially cover lupus drug Benlysta and could expand to other GSK specialty-care products in the future.

With a new £131 million contribution from the U.K. government, VMIC aims to both speed up and expand on its prior ambitions.

Pricing controversies shouldn't overshadow Phlow's promise to provide low-cost drugs to address COVID-19, says the CEO of partner Civica Rx.